New combo aims to keep leukemia in check after remission
NCT ID NCT07539818
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding venetoclax to azacitidine as maintenance therapy helps adults with acute myeloid leukemia (AML) stay in remission longer. About 788 patients who achieved first remission after initial treatment will receive either azacitidine alone or azacitidine plus venetoclax for up to 12 cycles. The main goal is to see if the combination improves disease-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine and venetoclax
What this could lead to
If successful, this could offer a more effective maintenance therapy to keep AML in remission longer, potentially reducing relapse risk.
What could go wrong
This is an early-stage Phase 3 trial with no results yet. The combination may cause more side effects, and it's unclear if it will improve survival or just delay relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••